FAIRFIELD, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Bradley Pharmaceuticals, Inc. today announced that its Doak Dermatologics subsidiary has launched ROSULA(R) CLK(TM), a kit combining two topical skincare products currently marketed by Doak. The kit contains ROSULA(R) Clarifying Wash(TM) (Sodium Sulfacetamide 10% and Sulfur 4%) in a urea vehicle, and A-FIL(R) Cream (meradimate 5% and titanium dioxide 5%) sunscreen. The ROSULA(R) CLK(TM) kit is available by prescription only.
ROSULA(R) Clarifying Wash(TM), a cleanser offered in an elegant formulation and large size, is indicated for the treatment of acne vulgaris, acne rosacea and seborrheic dermatitis. The product was launched by Doak in June of this year. A-FIL(R) Cream is an opaque SPF-25 dual barrier sunscreen that reflects and absorbs ultraviolet rays.
"The American Academy of Dermatology* advises patients who suffer from acne vulgaris and acne rosacea to protect their skin using a broad-spectrum sunscreen with an SPF of 15 or higher," stated Daniel Glassman, President and CEO of Bradley Pharmaceuticals. "We feel that the combination of ROSULA(R) Clarifying Wash(TM) and A-FIL(R) brand sunscreen will allow patients to more easily follow this important treatment and skin care regimen and enhances patient care."
Important Product Safety Information About ROSULA(R) Clarifying Wash(TM):
ROSULA(R) Clarifying Wash(TM) is contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. ROSULA(R) Clarifying Wash(TM) is not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation.
For additional important information about ROSULA(R) CLK(TM) please view full prescribing information at www.bradpharm.com or request full prescribing information by contacting Bradley Pharmaceuticals at 973-882-1505.
Please visit Bradley Pharmaceuticals web site at: www.bradpharm.com.
About Bradley Pharmaceuticals, Inc.
Bradley Pharmaceuticals, Inc. was founded in 1985 as a specialty pharmaceutical company and markets to niche physician specialties in the U.S. and international markets. Bradley's success is based upon its core strengths in marketing and sales, which enable the company to Commercialize brands that fill unmet patient and physician needs; Develop new products through life cycle management; and In-License phase II and phase III drugs with long-term intellectual property protection that upon approval leverage Bradley's marketing and sales expertise to increase shareholder value. Bradley Pharmaceuticals is comprised of Doak Dermatologics, specializing in therapies for dermatology and podiatry; Kenwood Therapeutics, providing gastroenterology, OB/GYN, respiratory and other internal medicine brands; and A. Aarons, which markets authorized generic versions of Doak and Kenwood therapies.
*Source American Academy of Dermatology website
Safe Harbor for Forward-Looking Statements:
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements include statements that address activities, events or developments that Bradley expects, believes or anticipates will or may occur in the future. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Bradley's control. Actual results may differ materially from those projected. These risks and uncertainties include those described from time to time in Bradley's SEC filings, including its Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Except as required by law, Bradley undertakes no obligation to publicly update any forward-looking statement in this press release, whether as a result of new information, future events or otherwise.
CONTACT: Investor & Public Relations, Cecelia C. Heer of Bradley
Pharmaceuticals, Inc., +1-973-882-1505, ext. 252, firstname.lastname@example.org
Web site: http://www.bradpharm.com/